Filtered By:
Source: Journal of Stroke and Cerebrovascular Diseases
Condition: Hemorrhagic Stroke
Drug: Activase
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 16 results found since Jan 2013.
Imaging Negative Stroke: Diagnoses and Outcomes in Intravenous Tissue Plasminogen Activator–Treated Patients
Conclusions: Because most INS patients were found to have NNCI, which may represent either transient ischemic attack or aborted stroke, and there were no intracerebral hemorrhages in the INS group, our data support the safety of administering IV t-PA to all patients in whom acute ischemic stroke is clinically suspected. We have demonstrated that NNCI patients and stroke mimics are common, and future larger scale prospective studies are required to delineate the true frequencies of each and to evaluate differences in outcomes.
Source: Journal of Stroke and Cerebrovascular Diseases - October 7, 2013 Category: Neurology Authors: Ilana Spokoyny, Rema Raman, Karin Ernstrom, Brett C. Meyer, Thomas M. Hemmen Tags: Original Articles Source Type: research
Intravenous Thrombolysis with Neuroprotective Therapy by Edaravone for Ischemic Stroke Patients Older than 80 Years of Age
Background: Alteplase, a recombinant tissue plasminogen activator (tPA), was approved for patients with acute ischemic stroke within 3 hours of stroke onset in Japan in October 2005 at a dose of 0.6 mg/kg. The aim of this study was to assess the safety and efficacy of alteplase in elderly patients in Japan.Methods: One hundred twenty-nine consecutive patients who were admitted to our 5 hospital groups and who received intravenous tPA within 3 hours of stroke onset between January 2010 and December 2011 were divided into 2 groups by age (80 years of age [older group]) and by treatment with or without edaravone. Clinical bac...
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2013 Category: Neurology Authors: Syoichiro Kono, Kentaro Deguchi, Nobutoshi Morimoto, Tomoko Kurata, Toru Yamashita, Yoshio Ikeda, Hisashi Narai, Yasuhiro Manabe, Yoshiki Takao, Sanami Kawada, Kenichi Kashihara, Yasushi Takehisa, Satoshi Inoue, Hideki Kiriyama, Koji Abe Tags: Original Articles Source Type: research
Safety of Standard-dose (.9-mg/kg) Alteplase Intravenous Thrombolysis for Acute Ischemic Stroke in Afro–Caribbeans, French West Indies
Conclusions: The excess hemorrhagic risk after standard-dose alteplase infusion into older Afro–Caribbean patients warrants further study to determine the possible role of cerebral microangiopathy and should be evaluated in different black populations.
Source: Journal of Stroke and Cerebrovascular Diseases - June 23, 2014 Category: Neurology Authors: Nicolas Chausson, Stéphane Olindo, Julien Joux, Martine Saint-Vil, Mathieu Aveillan, Didier Smadja Tags: Original Articles Source Type: research
Thromboelastographic Changes in Patients Experiencing an Acute Ischemic Stroke and Receiving Alteplase
Conclusions: Our study suggests that thromboelastogram (TEG) is a useful tool for determining changes in the coagulation system of patients whom have received recombinant tissue plasminogen activator (rt-PA). Further study is needed to determine if TEG can be used to predict those patients who may be at higher risk of adverse events because of rt-PA.
Source: Journal of Stroke and Cerebrovascular Diseases - January 21, 2014 Category: Neurology Authors: A. Shaun Rowe, Christal L. Greene, Carolyn C. Snider, Roger C. Carroll, Brian F. Wiseman, Jennifer M. Henry, J. Russell Langdon, Robert M. Craft Tags: Original Articles Source Type: research
Thrombolytic Therapy of Acute Ischemic Stroke during Early Pregnancy
Thrombolytic treatment (recombinant tissue plasminogen activator [rt-PA]) has established efficacy in acute ischemic stroke, but pregnancy has been an exclusion criterion for all clinical trials that validated alteplase in acute stroke, so our knowledge about its use in this condition is limited.Herein we report the successful use of intravenous rt-PA thrombolysis, uncomplicated by neither hemorrhage development nor other complication in a woman who was 13 weeks pregnant with acute ischemic stroke.
Source: Journal of Stroke and Cerebrovascular Diseases - November 28, 2017 Category: Neurology Authors: Anne Landais, Hugo Chaumont, Rachel Dellis Tags: Case Studies Source Type: research
Fatal Intracranial Hemorrhage after Intravenous Thrombolytic Therapy for Acute Ischemic Stroke Associated with Cancer-related Nonbacterial Thrombotic Endocarditis
Nonbacterial thrombotic endocarditis (NBTE) is associated with hypercoagulability in patients with inflammatory states such as cancer and autoimmune diseases. Cardiac vegetations caused by NBTE often lead to life-threatening systemic thromboembolism that most frequently affects the brain, spleen, and kidneys. A 54-year-old woman diagnosed with ovarian cancer suddenly developed back pain and left hemiparesis. Although intravenous alteplase (rt-PA) therapy was administered to treat hyperacute ischemic infarction detected by magnetic resonance imaging, intracranial hemorrhage occurred in the left hemisphere several hours late...
Source: Journal of Stroke and Cerebrovascular Diseases - August 11, 2014 Category: Neurology Authors: Takuya Yagi, Kie Takahashi, Mariko Tanikawa, Morinobu Seki, Takato Abe, Norihiro Suzuki Tags: Case Reports Source Type: research
Cerebral Microbleeds are an Independent Predictor of Hemorrhagic Transformation Following Intravenous Alteplase Administration in Acute Ischemic Stroke
The objective of our study was to evaluate clinical, laboratory, and imaging predictors on forecasting the risk of hemorrhagic transformation following treatment with rt-PA. We also evaluated the factors associated with cerebral microbleeds that increase the risk of hemorrhagic transformation.
Source: Journal of Stroke and Cerebrovascular Diseases - February 2, 2018 Category: Neurology Authors: Nandakumar Nagaraja, Nudrat Tasneem, Amir Shaban, Sudeepta Dandapat, Uzair Ahmed, Bruno Policeni, Heena Olalde, Hyungsub Shim, Edgar A. Samaniego, Connie Pieper, Santiago Ortega-Gutierrez, Enrique C. Leira, Harold P. Adams Source Type: research
Follow-up Imaging After Thrombolysis: FIAT, A Randomized Trial
Current protocols for treatment of acute ischemic stroke with intravenous thrombolytics, such as alteplase (tPA) and tenecteplase (tNK), recommend the completion of a routine non-contrast head CT at 24 hours post treatment to evaluate for hemorrhage prior to the initiation of antiplatelet therapy for secondary stroke prevention. This guideline was instituted because it had been part of the protocol in the NINDS multicenter randomized placebo-controlled trial that showed the benefit of IV thrombolytics within 3 hours of stroke onset.
Source: Journal of Stroke and Cerebrovascular Diseases - April 15, 2023 Category: Neurology Authors: Burton Tabaac, Leah Dickstein, Kristen Gurnea, Argye E. Hillis Source Type: research
What is the Price of the Potential for a Meaningful Recovery following Intracerebral Hemorrhage?
In this issue of the Journal of Stroke and Cerebrovascular Diseases, Vardanyan and colleagues report on the cost-utility of minimally invasive surgery (MIS) with thrombolysis for spontaneous intracerebral hemorrhage (ICH) from the perspective of the United Kingdom (UK) National Health Service (NHS)1 using data from the Minimally Invasive Surgery Plus Alteplase in Intracerebral Hemorrhage Evacuation (MISTIE III) trial2 and the UK Sentinel Stroke National Audit Programme (SSNAP).3 The economic evaluation revealed that the incremental cost-effectiveness ratio for MIS with thrombolysis fell significantly above the UK's Nationa...
Source: Journal of Stroke and Cerebrovascular Diseases - July 27, 2021 Category: Neurology Authors: Lourdes R. Carhuapoma, Avni Kapadia, Henry A. Glick, Daniel F. Hanley Source Type: research
What are the risks of intracerebral haemorrhage due to alteplase after acute ischaemic stroke? Results from an individual patient data meta-analysis of randomised trials
【Background】Alteplase also increases the risk of intracerebral haemorrhage, but the factors determining the proportional and absolute risks are uncertain.
Source: Journal of Stroke and Cerebrovascular Diseases - March 18, 2017 Category: Neurology Authors: William Whiteley Source Type: research
Safety of Intravenous Thrombolysis in Chronic Intracranial Hemorrhage: A Five-Year Multicenter Study
Although the recently updated U.S. alteplase label removed “history of intracranial hemorrhage (ICH)” as a contraindication, there are very limited data on the safety of intravenous thrombolysis (IVT) in acute ischemic stroke (AIS) patients with chronic ICH. We sought to evaluate IVT safety in AIS patients with a history of ICH.
Source: Journal of Stroke and Cerebrovascular Diseases - October 31, 2017 Category: Neurology Authors: Ramin Zand, Georgios Tsivgoulis, Alireza Sadighi, Mantinderpreet Singh, Michael McCormack, Shima Shahjouei, Nitin Goyal, Nariman Noorbakhsh-Sabet, Anne W. Alexandrov, Andrei V. Alexandrov Source Type: research
Corrigendum to “Comparative Analysis of Fibrinolytic Properties of Alteplase, Tenecteplase and Urokinase in an in Vitro Clot Model of Intracerebral Haemorrhage. Journal of Stroke and Cerebrovascular Diseases, Vol. 29, No. 9 (September), 2020: 105073”
The authors regret an error in the author list, and this should appear as above. The authors regret any inconvenience caused.
Source: Journal of Stroke and Cerebrovascular Diseases - October 27, 2020 Category: Neurology Authors: Naureen Keric, Melanie Doebel, Harald Krenzlin, Elena Kurz, Yasemin Tanyildizi, Axel Heimann, Jochem Koenig, Oliver Kempski, Florian Ringel, Julia Masomi-Bornwasser Source Type: research
Effects of Edaravone, a Free Radical Scavenger, on Circulating Levels of MMP-9 and Hemorrhagic Transformation in Patients with Intravenous Thrombolysis Using Low-dose Alteplase
Matrix metalloproteinase-9 (MMP-9) plays a key role for the blood–brain barrier disruption and intravenous tissue plasminogen activator (iv-tPA) therapy increases MMP-9. Edaravone, a free radical scavenger, reduces MMP-9–related blood–brain barrier disruption. We aimed to investigate whether edaravone would suppress the MMP-9 increase after iv-tPA using low-dose alteplase (0.6 mg/kg).
Source: Journal of Stroke and Cerebrovascular Diseases - October 2, 2014 Category: Neurology Authors: Atsushi Tsuruoka, Chihiro Atsumi, Heisuke Mizukami, Takeshi Imai, Yuta Hagiwara, Yasuhiro Hasegawa Source Type: research
Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models
Objective: Thrombolytic therapy with intravenous alteplase (IV-rtPA) has a known risk of symptomatic intracerebral hemorrhage (sICH). We aim to identify factors with a significant association with the development of sICH post-IV-rtPA. We also aim to perform an external validation of sICH predicting scores in our patient population. Material and Methods: We performed a retrospective chart review of patients who received IV-rtPA at our tertiary care hospital. We excluded patients who underwent mechanical thrombectomy.
Source: Journal of Stroke and Cerebrovascular Diseases - September 5, 2019 Category: Neurology Authors: Taha Nisar, Rajanigandhi Hanumanthu, Priyank Khandelwal Source Type: research
